Integrated Analysis and Identification of Novel Biomarkers in Parkinson’s Disease

Abstract

Parkinson's disease (PD) is a quite common neurodegenerative disorder with a prevalence of approximately 1:800-1,000 in subjects over 60 years old. The aim of our study was to determine the candidate target genes in PD through meta-analysis of multiple gene expression arrays datasets and to further combine mRNA and miRNA expression analyses to identify more convincing biological targets and their regulatory factors. Six included datasets were obtained from the Gene Expression Omnibus (GEO) database by systematical search, including five mRNA datasets (150 substantia nigra samples in total) and one miRNA dataset containing 32 peripheral blood samples. A chip meta-analysis of five microarray data was conducted by using the metaDE package and 94 differentially expressed(DE) mRNAs were comprehensively obtained. And Nineteen deregulated DE miRNAs were obtained through the analysis of one miRNAs dataset by Qlucore Omics Explorer (QOE) software. An interaction network formed by DE mRNAs, DE miRNAs and important pathways was discovered after we analysed the functional enrichment, protein–protein interactions and miRNA targetome prediction analysis. In conclusion, this study suggested that five significantly downregulated mRNAs (MAPK8, CDC42, NDUFS1, COX4I1 and SDHC) and three significantly downregulated miRNAs (miR-126-5p, miR-19-3p and miR-29a-3p) were potentially useful diagnostic markers in clinic, and lipid metabolism (especially non-alcoholic fatty liver disease (NAFLD) pathway) and mitochondrial dysregulation may be the keys to biochemically detectable molecular defects. However, the role of these new biomarkers and molecular mechanisms in PD requires further experiments in vivo and vitro and further clinical evidence.